Recent Updates — SLXN
Shareholders approved a resolution to increase the company's authorized share capital by 500,000,000 ordinary shares, raising the total from 15,900,000 to 515,900,000 shares. The vote also passed a proposal for a reverse stock split on a 1-for-24 basis, consolidating existing shares into fewer shares with a par value of $3.24. These governance changes were ratified at an extraordinary general meeting held on October 26, 2026. Silexion Therapeutics Corp operates in the biotechnology industry.
Silexion Therapeutics Corp announced the successful dosing of the first patient in its global Phase 2/3 clinical trial for SIL204, a second-generation small interfering RNA therapy targeting KRAS-driven locally advanced pancreatic cancer. The study employs an integrated regimen combining EUS-guided intratumoral delivery with subcutaneous injections alongside standard chemotherapy. The trial structure includes an initial safety run-in cohort of approximately 18 patients followed by a randomized expansion cohort of roughly 166 participants. Dosing commenced at Tel Aviv Sourasky Medical Center, with additional sites in Israel and Germany expected to activate soon. Silexion Therapeutics Corp is a clinical-stage biotechnology company developing RNA interference therapies for KRAS-driven solid tumors.
Silexion Therapeutics Corp entered into an inducement offer on September 28, 2026, allowing holders of 3,216,928 Series E warrants to exercise at a reduced price of $0.2603 per share, generating approximately $0.84 million in gross proceeds. In exchange, the company issued new Series F and Series G warrants for up to 6,433,856 shares at the same exercise price. The company also lowered the exercise price for all remaining outstanding Series E warrants (3,846,161 shares) to $0.2603 per share. H.C. Wainwright & Co., LLC served as placement agent, receiving 7% cash fees and warrants for 225,185 shares. The transaction is expected to close on September 29, 2026. Silexion Therapeutics Corp operates in the biotechnology industry, focusing on drug discovery.
Silexion Therapeutics Corp received a delisting notice from Nasdaq on August 18, 2026, for failing to maintain the minimum $2.5 million shareholders' equity requirement under Listing Rule 5550(b)(1). The company reported shareholders’ equity of only $44,000 as of June 30, 2026, and does not meet alternative continued listing standards. Silexion intends to appeal the determination before a Nasdaq Hearings Panel by August 25, 2026. The company is subject to a Mandatory Hearings Panel Monitor following a September 23, 2025 decision, which prevents Nasdaq from granting additional time for compliance during the one-year monitoring period. If the appeal fails, trading in ordinary shares and warrants would be suspended and removed from Nasdaq listing. Silexion Therapeutics Corp operates as a clinical-stage biopharmaceutical company focused on developing novel therapies.
Silexion Therapeutics Corp filed a Current Report on Form 8-K to announce the retroactive adjustment of its audited financial statements for the year ended December 31, 2025, and unaudited interim financial statements for the quarter ended March 31, 2026. These adjustments reflect a 1-for-10 reverse share split that was effected on May 28, 2026, following shareholder approval at an extraordinary general meeting held in April and May 2026. The adjusted financial statements are attached as Exhibit 99.1 and incorporated by reference into the filing. Silexion Therapeutics Corp operates in the biotechnology industry, developing RNA interference therapies for KRAS-driven cancers.